EFFECTS ON HEALTH AND COSTS OF DELAYED IMPLEMENTATION OF THE ONCOTYPE DX® TEST FOR ELIGIBLE BREAST CANCER PATIENTS

被引：0
|
作者：
Appelberg, K. [1 ]
Wilking, N. [2 ]
Levin, L. A. [1 ]
机构：
[1] Linkoping Univ, Linkoping, Sweden
[2] Karolinska Inst, Solna, Sweden
来源：
VALUE IN HEALTH | 2024年 / 27卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE93
引用
收藏
页码：S72 / S72
页数：1
相关论文
共 50 条
  • [21] Impact of Oncotype DX Testing for the Management of Patients With Intermediate Risk Breast Cancer
    Roe, Helen
    CANCER NURSING, 2016, 39 : S87 - S87
  • [22] The University of Kentucky Model for Selecting Breast Cancer Patients for Oncotype DX Testing
    Frame, S.
    Burge, M.
    Miller, N.
    Brill, Y.
    Matnani, R.
    McGrath, P.
    Fjallskog, M. L.
    Samayoa, L. M.
    LABORATORY INVESTIGATION, 2012, 92 : 40A - 40A
  • [23] Routine practice use of Oncotype Dx assay in French breast cancer patients
    Wassermann, J.
    Toledano, A.
    Gligorov, J.
    Conforti, R.
    Grapin, J. P.
    Benothman, S.
    Spano, J. P.
    Khayat, D.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S323 - S323
  • [24] Oncotype DX® Breast Recurrence ScoreTM (RS) distribution in primary breast cancer patients in Germany
    Hartkopf, A.
    Wallwiener, M.
    Andress, J.
    Walter, C.
    Chao, C.
    Turner, M.
    Weidenauer, H.
    Hahn, M.
    Taran, A.
    BREAST, 2017, 32 : S94 - S94
  • [25] Comparison of breast cancer prognostic tests CanAssist Breast and Oncotype DX
    Sengupta, Aditya K.
    Gunda, Aparna
    Malpani, Sukriti
    Serkad, Chandra Prakash, V
    Basavaraj, Chetana
    Bapat, Ashok
    Bakre, Manjiri M.
    CANCER MEDICINE, 2020, 9 (21): : 7810 - 7818
  • [26] Comparison of EndoPredict and Oncotype DX Test Results in Hormone Receptor Positive Invasive Breast Cancer
    Varga, Zsuzsanna
    Sinn, Peter
    Fritzsche, Florian
    von Hochstetter, Arthur
    Noske, Aurelia
    Schraml, Peter
    Tausch, Christoph
    Trojan, Andreas
    Moch, Holger
    PLOS ONE, 2013, 8 (03):
  • [27] Budget impact of the Oncotype DX® test compared to other gene expression tests in patients with early breast cancer in Germany
    Lux, M. P.
    Minartz, C.
    Mueller-Huesmann, H.
    Sandor, M. F.
    Herrmann, K. H.
    Radeck-Knorre, S.
    Neubauer, A. S.
    CANCER TREATMENT AND RESEARCH COMMUNICATIONS, 2022, 31
  • [28] Evaluation of the role of pharmacy technicians in reviewing the eligibility for Oncotype DX genomic test and the impact of the test on treatment plans in breast cancer patients
    Cheng, Vian
    Markarian, Adeline
    de Lemos, Mario L.
    Schaff, Kimberly
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2019, 25 (05) : 1167 - 1173
  • [29] Budget impact of Oncotype DX test compared to further gene expression tests in patients with early breast cancer in Germany
    Lux, M. P.
    Minartz, C.
    Muller-Huesmann, H.
    Sandor, M-F.
    Herrmann, K. H.
    Radeck-Knorre, S.
    Neubauer, A. S.
    ANNALS OF ONCOLOGY, 2021, 32 : S922 - S922
  • [30] Current controversies in the use of Oncotype DX in early breast cancer
    Giachetti, Pier Paolo M. Berton
    Schianca, Ambra Carnevale
    Trapani, Dario
    Marra, Antonio
    Toss, Angela
    Marchio, Caterina
    Dieci, Maria Vittoria
    Gentilini, Oreste Davide
    Criscitiello, Carmen
    Kalinsky, Kevin
    Sparano, Joseph A.
    Curigliano, Giuseppe
    CANCER TREATMENT REVIEWS, 2025, 135
12345